Takeda Pharmaceutical spinout HilleVax broke the biotech IPO drought with a $200 million stock market debut for clinical development of a norovirus vaccine. Two eye health companies marked the other IPO activity: Belite Bio went public while Bausch + Lomb set financial terms for what could become one of the biggest IPOs of the year.
HilleVax, Inc. (HLVX) expects to raise $175 million in an initial public offering on Friday, April 29th, IPO Scoop reports. The company will issue 10,300,000 shares at a price of $16.00-$18.00 per share. HilleVax, Inc. has a market cap of $513.2 million. J.P. Morgan, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for […]